Kasra Shakeri‐Nejad

Pharmacokinetics and Pharmacodynamics of Dabigatran Etexilate, an Oral Direct Thrombin Inhibitor, Are Not Affected by Moderate Hepatic Impairment

Joachim Stangier, Hildegard Stähle, Karin Rathgen et al. · The Journal of Clinical Pharmacology · 2008 · 172 citations

Dabigatran Etexilate, Pathology, Moderate Hepatic Impairment +18

Impact of siponimod on vaccination response in a randomized, placebo-controlled study

Mike Ufer, Kasra Shakeri‐Nejad, Anne Gardin et al. · Neurology Neuroimmunology & Neuroinflammation · 2017 · 36 citations · Full text

<scp>AQW</scp>051, a novel, potent and selective<scp>α</scp>7 nicotinic<scp>ACh</scp>receptor partial agonist: pharmacological characterization and phase<scp>I</scp>evaluation

Dominik Feuerbach, Nicole Pezous, Kasra Shakeri‐Nejad et al. · British Journal of Pharmacology · 2014 · 32 citations · Full text

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects

Anne Gardin, Mike Ufer, Eric Legangneux et al. · Clinical Pharmacokinetics · 2018 · 28 citations · Full text

Pharmacokinetics, safety, and tolerability of siponimod (BAF312) in subjects with different levels of hepatic impairment: a single-dose, open-label, parallel-group study

Kasra Shakeri‐Nejad, Vassilios Aslanis, Uday Kiran Veldandi et al. · International Journal of Clinical Pharmacology and Therapeutics · 2016 · 14 citations